MCID: DFF016
MIFTS: 48

Diffuse Astrocytoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Diffuse Astrocytoma

MalaCards integrated aliases for Diffuse Astrocytoma:

Name: Diffuse Astrocytoma 12 12 20 58 70
Fibrillary Astrocytoma 12 20 58 54 15 70
Gemistocytic Astrocytoma 20 70
Protoplasmic Astrocytoma 20 70
Diffuse Astrocytoma, Low Grade 12
Low-Grade Diffuse Astrocytoma 20
Fibrillary Astrocytic Tumors 12
Who Grade Ii Astrocytoma 12

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4857 DOID:6726
MeSH 44 D001254
NCIt 50 C4322 C7173
SNOMED-CT 67 71314006
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 71 C0280785 C0334582
UMLS 70 C0280785 C0334580 C0334581 more

Summaries for Diffuse Astrocytoma

Disease Ontology : 12 A malignant astrocytoma that is characterized as a low grade astrocytoma and has material basis in neoplastic astrocytes.

MalaCards based summary : Diffuse Astrocytoma, also known as fibrillary astrocytoma, is related to glioma susceptibility 1 and low grade glioma, and has symptoms including seizures, headache and motor manifestations. An important gene associated with Diffuse Astrocytoma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), and among its related pathways/superpathways are DNA Damage/Telomere Stress Induced Senescence and Shigellosis. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and spinal cord, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Diffuse Astrocytoma

Diseases related to Diffuse Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 285)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 31.3 TP53 IDH2 IDH1 H3-3A
2 low grade glioma 30.7 MGMT IDH2 IDH1
3 intracranial meningioma 30.5 PCNA MGMT
4 cerebellar astrocytoma 30.4 KIAA1549 IDH1 BRAF
5 glioma 30.3 TP53 IDH2 IDH1 H3-3A EGFR BRAF
6 melanoma, cutaneous malignant 1 30.1 TP53 MGMT BRAF AKT1
7 oligoastrocytoma 30.1 MGMT IDH2 GFAP
8 gliofibroma 30.0 TP53 MGMT KIAA1549 IDH1 GFAP
9 gemistocytic astrocytoma 29.8 TP53 IDH2 IDH1 GFAP ATRX
10 glioblastoma 29.8 TP53 MGMT IDH2 IDH1 H3-3A GFAP
11 pilocytic astrocytoma 29.7 TP53 MGMT KIAA1549 IDH1 GFAP BRAF
12 meningioma, familial 29.7 TP53 PCNA KIAA1549 H2AC18 GFAP EGFR
13 diffuse midline glioma, h3 k27m-mutant 29.5 TP53 MGMT KIAA1549 IDH1 H3-3B H3-3A
14 oligodendroglioma 29.5 TP53 PCNA MGMT IDH2 IDH1 GFAP
15 malignant astrocytoma 29.3 TP53 MGMT KIAA1549 KDM4C IDH2 IDH1
16 high grade glioma 29.2 TP53 MGMT IDH2 IDH1 H3-3A GFAP
17 pleomorphic xanthoastrocytoma 29.1 TP53 MGMT MAP2 KIAA1549 IDH1 H3-3B
18 giant cell glioblastoma 29.1 TP53 MGMT IDH2 IDH1 H3-3B H3-3A
19 anaplastic astrocytoma 29.0 TP53 MGMT KDM4C IDH2 IDH1 H3-3B
20 gliosarcoma 29.0 TP53 MGMT IDH2 IDH1 H3-3A H2AC18
21 protoplasmic astrocytoma 11.5
22 glial tumor 11.1
23 enchondroma 10.5 IDH2 IDH1
24 nevus of ota 10.5 TP53 BRAF
25 papillary tumor of the pineal region 10.4 MAP2 BRAF
26 cytogenetically normal acute myeloid leukemia 10.4 IDH2 IDH1
27 brain sarcoma 10.4 TP53 KIAA1549
28 spitz nevus 10.4 TP53 BRAF
29 laryngeal neuroendocrine tumor 10.4 TP53 IDH1
30 intracranial chondrosarcoma 10.4 IDH2 IDH1
31 pilocytic astrocytoma of cerebellum 10.4 KIAA1549 IDH1 BRAF
32 cystadenocarcinoma 10.4 TP53 BRAF AKT1
33 periosteal chondrosarcoma 10.4 IDH2 IDH1
34 high-grade astrocytoma 10.4 TP53 IDH1 ATRX
35 pediatric meningioma 10.4 LUC7L2 KIAA1549
36 juxtacortical chondroma 10.4 KDM4C IDH2 IDH1
37 extraventricular neurocytoma 10.4 IDH1 GFAP
38 anal squamous cell carcinoma 10.3 TP53 MGMT AKT1
39 anaplastic oligodendroglioma 10.3 MGMT IDH2
40 desmoplastic infantile ganglioglioma 10.3 GFAP BRAF
41 rhabdoid tumor predisposition syndrome 1 10.3 TP53 ATRX
42 thalamic neoplasm 10.3 MYBL1 KIAA1549
43 d-2-hydroxyglutaric aciduria 1 10.3 KDM4C IDH2 IDH1
44 2-hydroxyglutaric aciduria 10.3 KDM4C IDH2 IDH1
45 l-2-hydroxyglutaric aciduria 10.3 KDM4C IDH2 IDH1
46 esophagus verrucous carcinoma 10.3 TP53 EGFR
47 serous cystadenocarcinoma 10.3 TP53 BRAF AKT1
48 temporal lobe neoplasm 10.3 MGMT IDH1 ATRX
49 urethra transitional cell carcinoma 10.3 TP53 GFAP
50 bizarre leiomyoma 10.3 TP53 PCNA

Graphical network of the top 20 diseases related to Diffuse Astrocytoma:



Diseases related to Diffuse Astrocytoma

Symptoms & Phenotypes for Diffuse Astrocytoma

UMLS symptoms related to Diffuse Astrocytoma:


seizures; headache; motor manifestations; sensory manifestations

GenomeRNAi Phenotypes related to Diffuse Astrocytoma according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.72 GAP43
2 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.72 GAP43
3 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.72 GAP43
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.72 GAP43
5 Increased shRNA abundance (Z-score > 2) GR00366-A-144 9.72 GAP43
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.72 BRAF
7 Increased shRNA abundance (Z-score > 2) GR00366-A-150 9.72 KDM4C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.72 IDH2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.72 IDH2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.72 IDH2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.72 GAP43
12 Increased shRNA abundance (Z-score > 2) GR00366-A-188 9.72 KDM4C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.72 IDH2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-209 9.72 KDM4C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.72 GAP43
16 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.72 AKT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-216 9.72 IDH2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-27 9.72 IDH2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.72 IDH2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.72 BRAF
21 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.72 AKT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.72 AKT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.72 KDM4C
24 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 IDH2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 AKT1
26 Decreased p24 protein expression GR00163-A-1 9.26 AKT1 EGFR H3-3A IDH1

MGI Mouse Phenotypes related to Diffuse Astrocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10 AKT1 ATRX BRAF CENPF EGFR GAP43
2 mortality/aging MP:0010768 9.8 AKT1 ATRX BRAF CENPF EGFR GAP43
3 neoplasm MP:0002006 9.17 AKT1 BRAF EGFR IDH2 KDM4C MGMT

Drugs & Therapeutics for Diffuse Astrocytoma

Drugs for Diffuse Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3 Protein Kinase Inhibitors Phase 4
4
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
5
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
6
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
7
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
8
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
9 Vaccines Phase 2
10 Immunosuppressive Agents Phase 2
11 Tubulin Modulators Phase 2
12 Antimitotic Agents Phase 2
13 Immunologic Factors Phase 2
14 Immunoglobulins Phase 2
15 Antibodies Phase 2
16 Immunoglobulins, Intravenous Phase 2
17 Immunoglobulin G Phase 2
18 Antibodies, Monoclonal Phase 2
19
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
20 Alkylating Agents Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma Completed NCT01635283 Phase 2
3 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 Everolimus
4 Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) Recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
5 A Phase 1, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of CC-90010 in Preoperative Subjects With Progressive or Recurrent Who Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and Recurrent Glioblastoma Scheduled for Resection Active, not recruiting NCT04047303 Phase 1, Phase 2 CC-90010
6 A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Not yet recruiting NCT04729959 Phase 2
7 A Phase 1b Trial of CB-839 in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma Recruiting NCT03528642 Phase 1 Telaglenastat Hydrochloride;Temozolomide
8 Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients With Supratentorial Low-Risk Grade II Glioma Completed NCT01417507

Search NIH Clinical Center for Diffuse Astrocytoma

Genetic Tests for Diffuse Astrocytoma

Anatomical Context for Diffuse Astrocytoma

MalaCards organs/tissues related to Diffuse Astrocytoma:

40
Brain, Eye, Spinal Cord, Endothelial, Cortex, Cerebellum, Uterus

Publications for Diffuse Astrocytoma

Articles related to Diffuse Astrocytoma:

(show top 50) (show all 526)
# Title Authors PMID Year
1
Anaplastic astrocytoma during pregnancy: the importance of an effective multidisciplinary approach. 61
33795261 2021
2
High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma. 61
33454902 2021
3
Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review. 61
33389563 2021
4
Residential Proximity to Pesticide Application as a Risk Factor for Childhood Central Nervous System Tumors. 61
33798513 2021
5
IDH-mutant gliomas with additional class-defining molecular events. 61
33772213 2021
6
Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity. 61
33606385 2021
7
Illustration of the Added Value of 18F-DOPA PET to Multimodal MRI to Distinguish Low- and High-Grade Gliomas. 61
33577196 2021
8
Diffuse astrocytoma and the diagnostic dilemma of an unusual phenotype: A case report. 61
33304444 2021
9
A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis. 61
33634261 2021
10
Surgical treatment and neurological outcome of infiltrating intramedullary astrocytoma WHO II-IV: a multicenter retrospective case series. 61
33094355 2021
11
T2-FLAIR Mismatch Sign and Response to Radiotherapy in Diffuse Intrinsic Pontine Glioma. 61
33535215 2021
12
A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF A598T mutation. 61
32996219 2020
13
Serum cytokines in astrocytic brain tumors: a prospective study. 61
33349075 2020
14
Early atypical malignant transformation of diffuse low-grade astrocytoma: The importance of genotyping. 61
33162332 2020
15
[Diffuse Astrocytoma with Malignant Progression after Long-term Temozolomide Monotherapy:A Case Report]. 61
33071231 2020
16
IDH-wildtype secondary glioblastoma arising in IDH-mutant diffuse astrocytoma: a case report. 61
33095064 2020
17
A Case of Diffuse Astrocytoma with 32-year Survival after Boron Neutron Capture Therapy. 61
33062571 2020
18
Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. 61
33009979 2020
19
[Diffuse Leptomeningeal Glioneuronal Tumor with Subarachnoid Hemorrhage:A Case Report]. 61
32938808 2020
20
Histopathological Spectrum of Central Nervous System Tumors: an Experience at a Hospital in Nepal. 61
32969381 2020
21
Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis. 61
32052049 2020
22
Risk Stratification in Low Grade Glioma: A Single Institutional Experience. 61
32859817 2020
23
ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data. 61
32736562 2020
24
The expression level of cannabinoid receptors type 1 and 2 in the different types of astrocytomas. 61
32623617 2020
25
Unexpected discovery of a diffuse astrocytoma of the conus medullaris in an elderly NF1 patient. 61
32322332 2020
26
1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma. 61
32305004 2020
27
Favorable prognosis in pediatric brainstem low-grade glioma: Report from the German SIOP-LGG 2004 cohort. 61
31613986 2020
28
T2-FLAIR mismatch sign in dysembryoplasticneuroepithelial tumor. 61
32193035 2020
29
Neuroimaging Findings in Children with Constitutional Mismatch Repair Deficiency Syndrome. 61
32354708 2020
30
Eslicarbazepine in patients with brain tumor-related epilepsy: a single-center experience. 61
32316814 2020
31
Seizure freedom from recurrent insular low-grade glioma following laser interstitial thermal therapy. 61
31927616 2020
32
The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas. 61
32359929 2020
33
Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases. 61
31435963 2020
34
Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma. 61
32034238 2020
35
Association of the FGFR1 mutation with spontaneous hemorrhage in low-grade gliomas in pediatric and young adult patients. 61
32059187 2020
36
Surgical treatment of low-grade brain tumors associated with epilepsy. 61
32448606 2020
37
Morphological and immunophenotypic characterization of perivascular interstitial cells in human glioma: Telocytes, pericytes, and mixed immunophenotypes. 61
32064038 2020
38
TRPM7 Induces Tumorigenesis and Stemness Through Notch Activation in Glioma. 61
33381038 2020
39
Textiloma Mimicking a Recurrent High-Grade Astrocytoma: A Case Report. 61
32206542 2020
40
Prognostic Factors and Nomogram Predicting Survival in Diffuse Astrocytoma. 61
32140017 2020
41
Epithelioid glioblastoma presenting as multicentric glioma: A case report and review of the literature. 61
31966927 2020
42
Evaluation of the melting temperature of TaqMan probes as a genotyping method for IDH1, IDH2, and H3F3A in pediatric astrocytomas. 61
33186344 2020
43
High Dimensional Mass Cytometry Analysis Reveals Characteristics of the Immunosuppressive Microenvironment in Diffuse Astrocytomas. 61
32117733 2020
44
Eliciting Smiles and Laughter During Intraoperative Electric Stimulation of the Cingulum: Surgical Scenario. 61
31562962 2020
45
99mTc-CXCR4-L for Imaging of the Chemokine-4 Receptor Associated with Brain Tumor Invasiveness: Biokinetics, Radiation Dosimetry, and Proof of Concept in Humans. 61
32410920 2020
46
Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. 61
31563982 2020
47
IDH-1 polymorphisms in pilocytic astrocytomas. 61
31677487 2019
48
Spinal rosette-forming glioneuronal tumor: A case report. 61
31804365 2019
49
Nasopharyngeal Papillary Adenocarcinoma as a Second Head and Neck Malignancy. 61
29923095 2019
50
Tumor-associated status epilepticus in patients with glioma: Clinical characteristics and outcomes. 61
31300386 2019

Variations for Diffuse Astrocytoma

Expression for Diffuse Astrocytoma

Search GEO for disease gene expression data for Diffuse Astrocytoma.

Pathways for Diffuse Astrocytoma

Pathways related to Diffuse Astrocytoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.17 TP53 H3-3B H3-3A H2AC18
2 12.16 TP53 H3-3B H3-3A EGFR AKT1
3 12.12 TP53 EGFR BRAF AKT1
4
Show member pathways
12.04 TP53 MAP2 EGFR BRAF AKT1
5 12.01 TP53 EGFR BRAF AKT1
6 11.99 PCNA EGFR BRAF AKT1
7 11.95 TP53 EGFR BRAF AKT1
8
Show member pathways
11.83 TP53 EGFR BRAF AKT1
9 11.78 TP53 GFAP GAP43 EGFR
10
Show member pathways
11.66 TP53 H3-3B H3-3A EGFR AKT1
11 11.58 TP53 EGFR BRAF
12 11.4 TP53 MGMT EGFR BRAF AKT1
13 11.38 TP53 MYBL1 ATRX AKT1
14 10.87 TP53 IDH2 IDH1 EGFR AKT1
15
Show member pathways
10.66 IDH2 IDH1

GO Terms for Diffuse Astrocytoma

Cellular components related to Diffuse Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.17 TP53 PCNA MYBL1 MGMT LUC7L2 KDM4C
2 nucleoplasm GO:0005654 10 TP53 PCNA MYBL1 MGMT LUC7L2 KDM4C
3 Barr body GO:0001740 9.16 H3-3B H3-3A
4 nuclear chromosome GO:0000228 9.13 H3-3B H3-3A ATRX
5 chromosome, telomeric region GO:0000781 8.92 PCNA H3-3B H3-3A ATRX

Biological processes related to Diffuse Astrocytoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 TP53 MGMT EGFR BRAF AKT1
2 cellular response to DNA damage stimulus GO:0006974 9.96 TP53 PCNA MGMT ATRX AKT1
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.76 EGFR BRAF AKT1
4 cellular response to drug GO:0035690 9.71 TP53 EGFR BRAF
5 epidermal growth factor receptor signaling pathway GO:0007173 9.69 EGFR BRAF AKT1
6 positive regulation of DNA repair GO:0045739 9.61 PCNA MGMT EGFR
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.58 TP53 EGFR
8 mammary gland epithelial cell differentiation GO:0060644 9.57 MGMT AKT1
9 NADP metabolic process GO:0006739 9.55 IDH2 IDH1
10 isocitrate metabolic process GO:0006102 9.52 IDH2 IDH1
11 pericentric heterochromatin assembly GO:0031508 9.49 H3-3B H3-3A
12 regulation of centromere complex assembly GO:0090230 9.48 H3-3B H3-3A
13 response to UV-A GO:0070141 9.46 EGFR AKT1
14 positive regulation of cell growth GO:0030307 9.46 H3-3B H3-3A EGFR AKT1
15 DNA replication-independent nucleosome assembly GO:0006336 9.43 H3-3B H3-3A ATRX
16 negative regulation of chromosome condensation GO:1902340 9.4 H3-3B H3-3A
17 telomeric heterochromatin assembly GO:0031509 9.37 H3-3B H3-3A
18 glyoxylate cycle GO:0006097 9.32 IDH2 IDH1
19 multicellular organism growth GO:0035264 9.26 TP53 H3-3B H3-3A ATRX
20 response to oxidative stress GO:0006979 9.02 TP53 PCNA IDH1 EGFR AKT1

Molecular functions related to Diffuse Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.62 MAP2 GAP43 EGFR AKT1
2 chromatin binding GO:0003682 9.43 TP53 PCNA KDM4C EGFR CENPF ATRX
3 nitric-oxide synthase regulator activity GO:0030235 9.37 EGFR AKT1
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH2 IDH1
5 isocitrate dehydrogenase activity GO:0004448 9.16 IDH2 IDH1
6 enzyme binding GO:0019899 9.1 TP53 PCNA LUC7L2 KDM4C EGFR AKT1

Sources for Diffuse Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....